<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:st1="urn:schemas-microsoft-com:office:smarttags" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<meta name=Generator content="Microsoft Word 11 (filtered medium)">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><o:SmartTagType
namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="PostalCode"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="State"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="Street"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="PlaceName"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="PlaceType"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="country-region"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="address"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="City"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="place"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="PersonName"/>
<!--[if !mso]>
<style>
st1\:*{behavior:url(#default#ieooui) }
</style>
<![endif]-->
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman";}
a:link, span.MsoHyperlink
{color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{color:blue;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-reply;
font-family:Arial;
color:navy;}
@page Section1
{size:8.5in 11.0in;
margin:53.0pt 29.0pt 14.0pt 65.0pt;}
div.Section1
{page:Section1;}
-->
</style>
</head>
<body lang=EN-US link=blue vlink=blue>
<div class=Section1>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'>Dear Carlos,<o:p></o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'><o:p> </o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'>Most interesting information and thoughts
! <o:p></o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'><o:p> </o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'>I have not come across publications about recovery
of Leishmania from human and animal genital/oral mucosa. This may be inferred from
published records on the transmission of leishmaniasis via sexual activities
and blood transfusion in humans and dogs. Transmission via these and
congenital routes have always been considered as very rare, except perhaps for
the canine leishmaniasis in the <st1:country-region w:st="on"><st1:place w:st="on">USA</st1:place></st1:country-region>.
<o:p></o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'><o:p> </o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'>The zoonotic aspects of epidemiology in leishmaniasis
are most interesting and highly significant, but are difficult to study because
it requires lots of funding for long-term investigation. <st1:country-region
w:st="on"><st1:place w:st="on">Brazil</st1:place></st1:country-region> is
undoubtedly the place for such study, and Jeff and Sinval have contributed
significantly to this area. Sylvatic rodent, edentate and canine cycles of
transmission are already very complicated. It would be even more complicated,
should there be intersection among the 3 cycles and the involvement of domestic
dogs, as stated in your message, regardless of vector or non-vector
transmission. That makes the rat-rat, pig-pig and pig-rat cycles of
transmission in trichinosis very simple by comparison.<o:p></o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'><o:p> </o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'>KP<o:p></o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'><o:p> </o:p></span></font></p>
<div>
<div class=MsoNormal align=center style='text-align:center'><font size=3
face="Times New Roman"><span style='font-size:12.0pt'>
<hr size=2 width="100%" align=center tabindex=-1>
</span></font></div>
<p class=MsoNormal><b><font size=2 face=Tahoma><span style='font-size:10.0pt;
font-family:Tahoma;font-weight:bold'>From:</span></font></b><font size=2
face=Tahoma><span style='font-size:10.0pt;font-family:Tahoma'> <st1:PersonName
w:st="on">Carlos Costa</st1:PersonName> [mailto:chncosta@gmail.com] <br>
<b><span style='font-weight:bold'>Sent:</span></b> Saturday, October 22, 2011
8:14 AM<br>
<b><span style='font-weight:bold'>To:</span></b> Chang, Kwang-Poo<br>
<b><span style='font-weight:bold'>Cc:</span></b>
mauro.marzochi@ipec.fiocruz.br; leish-l@lineu.icb.usp.br<br>
<b><span style='font-weight:bold'>Subject:</span></b> Re: [Leish-l] RES:
testing vaccinated dogs for immunopotentiation</span></font><o:p></o:p></p>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
<div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'>Dear KP,</span></font><o:p></o:p></p>
</div>
<div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'><o:p> </o:p></span></font></p>
</div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'>Leishmania can be
recovered from genital & oral mucosa or secretions from humans and animals.
Direct transmission has been documented via blood transfusion, sex and vertical
in humans and dogs. So, it exists. The question reside in is its magnitude and
importance.</span></font><o:p></o:p></p>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'>It took me a few days
to respond to your call because I was searching my older references looking for
a particular one, actually an abstract of a meeting, showing that if you put
one infected hamster in sand fly-proof free cage, with time most will get
infected. Hopefully one of you will find it (or do it again), since I could not
find mine. </span></font><o:p></o:p></p>
</div>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'>Months ago, talking to
Dr. Sinval Brandão-Filho, the next host of WorldLeish, we wondered if a low
prevalence rodent cycle could not feed a dog cycle and thereafter human
transmission. It sounds logic if, and only if, in fact there is a rodent cycle
(some data suggest it does not, but others (Jeff Shaw's) that it does - any
way, this a critical point). The logic is that canids feed a lot on rodents
(and on opossums), and are very vulnerable, and go back to human dwellings. The
same would be valid for a purely sylvatic cycle among rodents/opossums and
foxes).</span></font><o:p></o:p></p>
</div>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'>Of course, rodents may
not be required if oral transmission among dogs is possible and common, as
American, Canadian and Dutch kennel data suggest. But since there is a large
overlap between the presence of sandflies and zoonotic kala-azar in endemic
countries such a transmission may have a limited role and may be restricted to
animals that are confined in groups or to stray dogs and sylvatic canids, but
not to solitary animals restricted to households.</span></font><o:p></o:p></p>
</div>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'>Any way, this a
largely under investigated subject, which can bring surprises to the presently
established & dominating knowledge. Deserves a lot of funding.</span></font><o:p></o:p></p>
</div>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=4 face=Verdana><span style='font-size:13.5pt;
font-family:Verdana'>One last note: if it shows to be indeed important, sandfly
challenge may not be required for vaccine evaluation. </span></font><o:p></o:p></p>
</div>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=4 color=black face=Verdana><span
style='font-size:13.5pt;font-family:Verdana;color:black'>Cheers,</span></font><o:p></o:p></p>
</div>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<div>
<p class=MsoNormal style='margin-bottom:12.0pt'><font size=4 color=black
face=Verdana><span style='font-size:13.5pt;font-family:Verdana;color:black'>Carlos.
</span></font><o:p></o:p></p>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'>2011/10/21 Chang, Kwang-Poo <<a
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</a>><o:p></o:p></span></font></p>
<p class=MsoNormal><st1:PersonName w:st="on"><font size=3 face="Times New Roman"><span
style='font-size:12.0pt'>Carlos Costa</span></font></st1:PersonName> brought
my attention to this possibility as well. Carlos may want to comment on this ?
Is this a hypothesis based on common sense or on observation/experimental data
?<br>
<font color="#888888"><span style='color:#888888'><br>
KP</span></font><o:p></o:p></p>
<div>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><br>
-----Original Message-----<br>
From: <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>
[mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]
On Behalf Of <a href="mailto:mauro.marzochi@ipec.fiocruz.br">mauro.marzochi@ipec.fiocruz.br</a><br>
Sent: Wednesday, October 19, 2011 2:26 PM<br>
To: <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
Subject: Re: [Leish-l] RES: testing vaccinated dogs for immunopotentiation<br>
<br>
Dear All,<br>
In the past, it was believed that in the Mediterranean region the<br>
visceral leishmaniasis transmission to children could be attributed to<br>
contamination of healthy children by the saliva of dogs infected with<br>
Leishmania infantum (Alencar?; Hommel?). Thus, the inter canine<br>
transmission in confined environments could not be established by the<br>
contamination of food shared between infected and uninfected dogs?<br>
<br>
Mauro C A Marzochi<br>
IPEC-Fiocruz/CNPq<br>
<br>
<br>
<br>
<br>
<br>
On Wed, 19 Oct 2011 08:25:45 -0500, <st1:PersonName w:st="on">Petersen,
Christine A [V PTH]</st1:PersonName><br>
wrote:<br>
> Dear all-<br>
> Thanks for the review. Vertical infection is maintaining infection<br>
> in dogs in the <st1:country-region w:st="on"><st1:place w:st="on">United
States</st1:place></st1:country-region>. We continue to look for vector<br>
> transmission, and despite having potential sand fly vectors, no<br>
> infected flies to date.<br>
> Christy Petersen<br>
> -----Original Message-----<br>
> From: <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a><br>
> [mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]
On Behalf Of Courtenay,<br>
> Orin<br>
> Sent: Wednesday, October 19, 2011 3:46 AM<br>
> To: <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>;
<a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a><br>
> Subject: Re: [Leish-l] RES: testing vaccinated dogs for<br>
> immunopotentiation<br>
><br>
> Dear all,<br>
> I attach a recent review of evidence for non-sandfly transmission<br>
> routes and cycles in different hosts.<br>
><br>
> It is worth distinguishing between vaccination outcomes: one that<br>
> provides individual protection versus one that provides community<br>
> protection (herd immunity) by interrupting the transmission cycle<br>
> (R0<1). The attached review concludes that vertical infection is very<br>
> unlikely to maintain transmission independent of the dog-sandfly-dog<br>
> cycle.<br>
><br>
> Orin<br>
><br>
><br>
> Dr. Orin Courtenay<br>
> Reader<br>
> <st1:place w:st="on"><st1:PlaceType w:st="on">School</st1:PlaceType> of <st1:PlaceName
w:st="on">Life Sciences</st1:PlaceName></st1:place><br>
> <st1:place w:st="on"><st1:PlaceType w:st="on">University</st1:PlaceType>
of <st1:PlaceName w:st="on">Warwick</st1:PlaceName></st1:place><br>
> <st1:Street w:st="on"><st1:address w:st="on">Gibbet Hill Road</st1:address></st1:Street><br>
> <st1:City w:st="on"><st1:place w:st="on">Coventry</st1:place></st1:City><br>
> CV4 7AL<br>
> ++44 +2476 524550<br>
> skype: orin.courtenay<br>
> <a href="mailto:orin.courtenay@warwick.ac.uk">orin.courtenay@warwick.ac.uk</a><br>
> <a href="http://www2.warwick.ac.uk/fac/sci/lifesci/people/ocourtenay/"
target="_blank">http://www2.warwick.ac.uk/fac/sci/lifesci/people/ocourtenay/</a><br>
><br>
> Emails over 10Mb will not reach me. If you want to send large files<br>
> use the following: <a
href="https://files.warwick.ac.uk/orincourtenay/sendto" target="_blank">https://files.warwick.ac.uk/orincourtenay/sendto</a><br>
><br>
><br>
><br>
> -----Original Message-----<br>
> From: <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a><br>
> [mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]
On Behalf Of Chang,<br>
> Kwang-Poo<br>
> Sent: 17 October 2011 18:54<br>
> To: Patrick Bastien; <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
> Subject: Re: [Leish-l] RES: testing vaccinated dogs for<br>
> immunopotentiation<br>
><br>
> Dear Patrick,<br>
><br>
> Thanks a lot for the article from <st1:country-region w:st="on"><st1:place
w:st="on">Brazil</st1:place></st1:country-region> about vertical transmission<br>
> of canine leishmaniasis. The work is significant and was done by<br>
> examining stillborn pups.<br>
><br>
> Christy's recent paper extended this and the other earlier finding of<br>
> Leishmania in fetus to live pups. Together, they constitute strong<br>
> evidence for vertical transmission of Leishmania in dogs. As pointed<br>
> out in the article, its potential significance in epidemiology awaits<br>
> further study. This is also true for its implication in considering<br>
> vaccination, etc.<br>
><br>
> KP<br>
><br>
><br>
><br>
> -----Original Message-----<br>
> From: <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a><br>
> [mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]
On Behalf Of Patrick<br>
> Bastien<br>
> Sent: Saturday, October 15, 2011 3:13 AM<br>
> To: <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
> Subject: Re: [Leish-l] RES: testing vaccinated dogs for<br>
> immunopotentiation<br>
><br>
> Dear KP,<br>
> That's it for article [3].<br>
> (don't ask me how I got this proof, I cant' remember).<br>
> Best wishes<br>
> P. Bastien<br>
><br>
> Professeur Patrick Bastien<br>
> Laboratoire de Parasitologie-Mycologie, Faculté de Médecine UMR<br>
> MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1) Centre<br>
> National de Référence des Leishmania CHU de Montpellier<br>
> 39 Avenue Charles Flahault<br>
> 34295 <st1:City w:st="on"><st1:place w:st="on">Montpellier</st1:place></st1:City>
Cedex 5, France<br>
><br>
> "Chang, Kwang-Poo" <<a
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</a>>
a écrit :<br>
><br>
>> I also recall the description of sexual transmission in human<br>
>> leishmaniasis in old literature, but this is rare.<br>
>><br>
>><br>
>> Going back to the issue of congenital transmission in human and<br>
>> canine leishmaiasis, I listed 3 articles below from a pubmed search.<br>
>><br>
>> [1] Pediatrics. 1999 Nov;104(5):e65.<br>
>> Congenital transmission of visceral leishmaniasis (Kala Azar) from<br>
>> an asymptomatic mother to her child.<br>
>> Meinecke CK, Schottelius J, Oskam L, Fleischer B.<br>
>> SourceChildren's Hospital of <st1:City w:st="on">Stuttgart</st1:City>
(Olgahospital), <st1:City w:st="on"><st1:place w:st="on">Stuttgart</st1:place></st1:City>,<br>
>> <st1:country-region w:st="on"><st1:place w:st="on">Germany</st1:place></st1:country-region>.<br>
>><br>
>><br>
>><br>
>> [2] J Parasitol. 2005 Aug;91(4):970-2.<br>
>> Transplacental transmission of a North American isolate of<br>
>> Leishmania infantum in an experimentally infected beagle.<br>
>> Rosypal AC, <st1:place w:st="on">T<st1:PersonName w:st="on">roy</st1:PersonName></st1:place>
GC, Zajac AM, Frank G, Lindsay DS.<br>
>> SourceDepartment of Biomedical Sciences and Pathobiology,<br>
>> <st1:PlaceName w:st="on">Virginia-Maryland</st1:PlaceName> <st1:PlaceName
w:st="on">Regional</st1:PlaceName> <st1:PlaceType w:st="on">College</st1:PlaceType>
of Veterinary Medicine, <st1:State w:st="on"><st1:place w:st="on">Virginia</st1:place></st1:State><br>
>> Tech, <st1:place w:st="on"><st1:City w:st="on">Blacksburg</st1:City>, <st1:State
w:st="on">Virginia</st1:State> <st1:PostalCode w:st="on">24061</st1:PostalCode>,
<st1:country-region w:st="on">USA</st1:country-region></st1:place><br>
>><br>
>> [3] Vet Parasitol. 2009 Dec 3;166(1-2):159-62. Epub 2009 Aug 15.<br>
>> First report of vertical transmission of Leishmania (Leishmania)<br>
>> infantum in a naturally infected bitch from <st1:country-region w:st="on"><st1:place
w:st="on">Brazil</st1:place></st1:country-region>.<br>
>> da Silva SM, Ribeiro VM, Ribeiro RR, Tafuri WL, Melo MN, Michalick<br>
>> MS.<br>
>> SourceDepartamento de Parasitologia, Instituto de Ciências<br>
>> Biológicas, Universidade Federal de Minas Gerais, 31270-901 Belo<br>
>> Horizonte, MG, <st1:country-region w:st="on"><st1:place w:st="on">Brazil</st1:place></st1:country-region>.<br>
>><br>
>> I hope Dr. Rosypal and the authors of article [3] could make the pdf<br>
>> reprints of their articles available, since they were published
in<br>
>> journals, which are not readily available.<br>
>><br>
>><br>
>><br>
>> KP<br>
>><br>
>> -----Original Message-----<br>
>> From: <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a><br>
>> [mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]
On Behalf Of Christopher<br>
>> Peacock<br>
>> Sent: Sunday, October 09, 2011 10:33 PM<br>
>> To: <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
>> Subject: Re: [Leish-l] RES: testing vaccinated dogs for<br>
>> immunopotentiation<br>
>><br>
>> Hi,<br>
>> There is also this rather bizarre story of a Gulf War veteran who<br>
>> returned with leishmaniasis, this link is a Veterans association<br>
>> website and suggest both sexual transmission and vertical<br>
>> transmission. Not sure how reliable this information is but it does<br>
>> seem to be contested in court. Would be interesting to know more<br>
>> details on this case and whether it has any evidence to support the<br>
>> cases, as far as I am aware there has only been one suggested case<br>
>> of sexually transmitted Leishmania in humans documented many years<br>
>> ago.<br>
>><br>
>> <a href="http://www.vawatchdog.org/07/nf07/nfJUN07/nf062907-3.htm"
target="_blank">http://www.vawatchdog.org/07/nf07/nfJUN07/nf062907-3.htm</a><br>
>><br>
>> <a href="http://www.leishmaniasis.us/Leish.html" target="_blank">http://www.leishmaniasis.us/Leish.html</a><br>
>><br>
>> Cheers<br>
>><br>
>> Chris<br>
>><br>
>> Associate Professor Christopher Peacock<br>
>> Discipline of Microbiology & Immunology M502<br>
>> School of Biomedical, Biomolecular & Chemical Sciences<br>
>> The <st1:place w:st="on"><st1:PlaceType w:st="on">University</st1:PlaceType>
of <st1:PlaceName w:st="on">Western Australia</st1:PlaceName></st1:place><br>
>> Nedlands WA 6009<br>
>><br>
>> ph 00 61(0)8 9287 6172<br>
>> fax 00 61(0)8 9346 2912<br>
>><br>
>> -----Original Message-----<br>
>> From: <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a><br>
>> [mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]
On Behalf Of Patrick<br>
>> Bastien<br>
>> Sent: Saturday, 8 October 2011 1:31 AM<br>
>> To: <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
>> Subject: Re: [Leish-l] RES: testing vaccinated dogs for<br>
>> immunopotentiation<br>
>><br>
>> There were several earlier reports of this vertical transmission,<br>
>> even<br>
>> in the <st1:country-region w:st="on"><st1:place w:st="on">US</st1:place></st1:country-region>:
among others, Rosypal AC, J.Parasitol. 2005, 970-972 and<br>
>> 113-115 Magno da Silva, Vet Parasitol 2009 Pangrazio, Vet Parasitol<br>
>> 2009<br>
>><br>
>> Best regards<br>
>> P. Bastien<br>
>><br>
>> Professeur Patrick Bastien<br>
>> Laboratoire de Parasitologie-Mycologie, Faculté de Médecine UMR<br>
>> MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1) Centre<br>
>> National de Référence des Leishmania CHU de Montpellier<br>
>> 39 Avenue Charles Flahault<br>
>> 34295 <st1:City w:st="on"><st1:place w:st="on">Montpellier</st1:place></st1:City>
Cedex 5, France<br>
>><br>
>> "Chang, Kwang-Poo" <<a
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</a>>
a écrit :<br>
>><br>
>>> What Jenni said indicates that transplacental transmission of<br>
>>> canine<br>
>>> leishmaniasis has some implication in considering dog vaccination.<br>
>>><br>
>>><br>
>>><br>
>>> Of further interest is the question of whether this transplacental<br>
>>> transmission could also occur in other reservoir animals or even
in<br>
>>> human leishmaniasis ? I recall the description of such
transmission<br>
>>> in human cases in some very early literature, but that has been<br>
>>> always considered as unlikely or extremely rare, more as a<br>
>>> hypothesis<br>
>>> than reality. This issue may have been addressed in more recent<br>
>>> epidemiological studies of VL familial clustering in<br>
>>> well-established<br>
>>> endemic sites ? Congenital transmission might escape our
attention,<br>
>>> should the outcome be largely asymptomatic ?<br>
>>><br>
>>><br>
>>><br>
>>> KP<br>
>>><br>
>>><br>
>>><br>
>>> ________________________________<br>
>>><br>
>>> From: Jennie Blackwell [mailto:<a href="mailto:jmb37@cam.ac.uk">jmb37@cam.ac.uk</a>]<br>
>>> Sent: Wednesday, October 05, 2011 6:46 PM<br>
>>> To: Chang, Kwang-Poo<br>
>>> Cc: <st1:PersonName w:st="on">Petersen, Christine A [V PTH]</st1:PersonName>;
TECSA - Luiz Ristow; John David;<br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
>>> Subject: Re: [Leish-l] RES: testing vaccinated dogs for<br>
>>> immunopotentiation<br>
>>><br>
>>><br>
>>><br>
>>> I doubt it. Treatment might but if the mum was already infected
and<br>
>>> passed the parasite to the foetus I don't see how a vaccine would<br>
>>> work to clear the parasite from the foetus!<br>
>>><br>
>>><br>
>>><br>
>>> Slightly different question as to whether vaccinating mums will<br>
>>> give<br>
>>> them sufficient protection to not pass the parasite to the pup in<br>
>>> utero should they get infected themselves after vaccination.<br>
>>><br>
>>><br>
>>><br>
>>> Cheers all, Jennie<br>
>>><br>
>>> Jenefer M. Blackwell<br>
>>><br>
>>> TICHR, CCHR, UWA<br>
>>><br>
>>> Phone: <a href="tel:%2B61%208%2094897910" value="+61894897910">+61
8 94897910</a><br>
>>><br>
>>> From my iPhone<br>
>>><br>
>>><br>
>>> On 29 Sep 2011, at 00:36, "Chang, Kwang-Poo"<br>
>>> <<a href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</a>>
wrote:<br>
>>><br>
>>> Of interest is the question of whether
vaccination would<br>
>>> clear<br>
>>> the infection of the pub, which has congenitally inherited L<br>
>>> infantum ?<br>
>>><br>
>>><br>
>>><br>
>>> KP<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> ________________________________<br>
>>><br>
>>><br>
>>> From: <st1:PersonName w:st="on">Petersen,
Christine A [V PTH]</st1:PersonName><br>
>>> [mailto:<a href="mailto:kalicat@iastate.edu">kalicat@iastate.edu</a>]<br>
>>><br>
>>> Sent: Wednesday, September 28, 2011 11:23 AM<br>
>>> To: Chang, Kwang-Poo; TECSA - Luiz Ristow;
John David<br>
>>> Cc: <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>;
<st1:PersonName w:st="on">Petersen, Christine A [V PTH]</st1:PersonName><br>
>>> Subject: RE: [Leish-l] RES: testing
vaccinated dogs for<br>
>>> immunopotentiation<br>
>>><br>
>>><br>
>>><br>
>>> The reference for this article is:<br>
>>> <<a href="http://www.ncbi.nlm.nih.gov/pubmed/21532741"
target="_blank">http://www.ncbi.nlm.nih.gov/pubmed/21532741</a>><br>
>>> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21532741"
target="_blank">http://www.ncbi.nlm.nih.gov/pubmed/21532741</a><br>
>>><br>
>>> As it was published in a PLoS journal its
free access to all.<br>
>>><br>
>>> Based on our studies and recent ones from <st1:country-region
w:st="on"><st1:place w:st="on">Brazil</st1:place></st1:country-region>, I do<br>
>>> believe<br>
>>> that to remove Leish from the canine reservoir, transmission from<br>
>>> mom<br>
>>> to pup will need to be addressed.<br>
>>><br>
>>> Christy Petersen<br>
>>><br>
>>><br>
>>><br>
>>> From: Chang, Kwang-Poo<br>
>>> [mailto:<a href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</a>]<br>
>>> Sent: Wednesday, September 28, 2011 10:20 AM<br>
>>> To: TECSA - Luiz Ristow; John David<br>
>>> Cc: <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>;
<st1:PersonName w:st="on">Petersen, Christine A [V PTH]</st1:PersonName><br>
>>> Subject: RE: [Leish-l] RES: testing
vaccinated dogs for<br>
>>> immunopotentiation<br>
>>><br>
>>><br>
>>><br>
>>> Christine Petersen published an article about
transplacental<br>
>>> transmission of L infantum in the <st1:country-region w:st="on"><st1:place
w:st="on">USA</st1:place></st1:country-region> canine leishmaniasis. I just<br>
>>> wonder about the implication of this finding in considering<br>
>>> vaccination against the disease transmitted this way ?<br>
>>><br>
>>><br>
>>><br>
>>> KP<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> ________________________________<br>
>>><br>
>>><br>
>>> From: <mailto:<a
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a><br>
>>> [mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]<br>
>>> <mailto:%<a
href="mailto:5bmailto%3Aleish-l-bounces@lineu.icb.usp.br">5bmailto:leish-l-bounces@lineu.icb.usp.br</a>%5d>
On Behalf<br>
>>> Of<br>
>>> TECSA - Luiz Ristow<br>
>>> Sent: Wednesday, September 28, 2011 9:08 AM<br>
>>> To: 'John David'<br>
>>> Cc: <mailto:<a
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
>>> Subject: [Leish-l] RES: testing vaccinated
dogs for<br>
>>> immunopotentiation<br>
>>><br>
>>><br>
>>><br>
>>> Hi !<br>
>>><br>
>>><br>
>>><br>
>>> There are these papers about<br>
>>><br>
>>> These need a very critical reading to discuss<br>
>>><br>
>>> This discussion with all about the matter and
these papers is<br>
>>> very welcome! (at least for me!)<br>
>>><br>
>>> Regards for all<br>
>>><br>
>>> Luiz Ristow<br>
>>><br>
>>><br>
>>><br>
>>> <image001.gif><br>
>>><br>
>>><br>
>>><br>
>>> De: <mailto:<a
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a><br>
>>> [mailto:<a href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</a>]<br>
>>> <mailto:%<a
href="mailto:5bmailto%3Aleish-l-bounces@lineu.icb.usp.br">5bmailto:leish-l-bounces@lineu.icb.usp.br</a>%5d>
Em nome de<br>
>>> John David<br>
>>> Enviada em: segunda-feira, 26 de setembro de
2011 18:44<br>
>>> <st1:place w:st="on">Para</st1:place>: Dr GR
Rajasekariah<br>
>>> Cc: <mailto:<a
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>;<br>
>>> Carlos Gouvea; hubert mazure; <mailto:<a
href="mailto:smithyman@cellabs.com.au">smithyman@cellabs.com.au</a>><br>
>>> <a href="mailto:smithyman@cellabs.com.au">smithyman@cellabs.com.au</a><br>
>>> Assunto: Re: [Leish-l] testing vaccinated
dogs for<br>
>>> immunopotentiation<br>
>>><br>
>>><br>
>>><br>
>>> I think that for any vaccine developed to
protect dogs<br>
>>> against<br>
>>> VL, but which is also meant to prevent transmission of VL to<br>
>>> humans,<br>
>>> the developers should show that after the vaccinated dog has been<br>
>>> challenged with Leishmania, it does not transmit Leishmania to
sand<br>
>>> flies.<br>
>>><br>
>>> John R David, M.D.<br>
>>><br>
>>> Richard Pearson Strong Professor Emeritus<br>
>>><br>
>>> Department of Immunology and Infectious
Diseases<br>
>>><br>
>>> <st1:place w:st="on"><st1:PlaceName w:st="on">Harvard</st1:PlaceName>
<st1:PlaceType w:st="on">School</st1:PlaceType></st1:place> of Public Health<br>
>>><br>
>>> Professor of Medicine, <st1:place w:st="on"><st1:PlaceName
w:st="on">Harvard</st1:PlaceName> <st1:PlaceName w:st="on">Medical</st1:PlaceName>
<st1:PlaceType w:st="on">School</st1:PlaceType></st1:place><br>
>>><br>
>>> <st1:address w:st="on"><st1:Street w:st="on">300
W. 23rd Street, Apt. 13</st1:Street>K</st1:address><br>
>>><br>
>>> <st1:place w:st="on"><st1:City w:st="on">New
York</st1:City>, <st1:State w:st="on">NY</st1:State>, <st1:PostalCode w:st="on">10011</st1:PostalCode></st1:place><br>
>>><br>
>>> Tel: <a href="tel:212%20414%208646"
value="+12124148646">212 414 8646</a><br>
>>><br>
>>> Email: <mailto:<a
href="mailto:jdavid@hsph.harvard.edu">jdavid@hsph.harvard.edu</a>><br>
>>> <a href="mailto:jdavid@hsph.harvard.edu">jdavid@hsph.harvard.edu</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> On Sep 19, 2011, at 12:04 AM, Dr GR
Rajasekariah wrote:<br>
>>><br>
>>><br>
>>><br>
>>> Hello EveryOne,<br>
>>> I am responding to the topic on European VL
Dog vaccine.<br>
>>> It is a great challenge in devising a
protective vaccine<br>
>>> against visceral leishmaniasis in dogs. This point equally applies<br>
>>> the same challenge for human situation.<br>
>>> Because Th-2 response is so dominant during
VL infection,<br>
>>> modulating Th-2 into Th-1 response is a big challenge to<br>
>>> immunologists.<br>
>>><br>
>>> Key points lies in the presentation of
appropriate antigen in<br>
>>> appropriate dose to stimulate the Th-1 dependent protective
immune<br>
>>> response.<br>
>>> I understand several vaccines are in the
market and real<br>
>>> efficacy of these vaccines will come out once introduced to field<br>
>>> conditions.<br>
>>><br>
>>> I just wanted to inform you that we have a
suitable antibody<br>
>>> kit for testing the immunopotentiation in dogs following<br>
>>> vaccination<br>
>>> of dogs.<br>
>>> Our assay is based on the released
promastigote antigens.<br>
>>> It is a highly sensitive assay.<br>
>>> Currently we supply reagents for
determination of total IgG<br>
>>> antibodies in serum.<br>
>>> If any particular group is interested then we
are able to<br>
>>> provide appropriate reagent for detection of specific IgG2 and<br>
>>> other<br>
>>> isotype specific antibody detection.<br>
>>> Because our antibody detection ELISA is based
on the<br>
>>> exo-antigens such an ELISA would be of exceptional type for<br>
>>> measuring<br>
>>> antibody response in vaccinated animals.<br>
>>> Highly suitable for diagnosing dogs responded
to vaccines.<br>
>>><br>
>>> Recently I came to know that some of
commercial kits were<br>
>>> found to be not useful for detecting seroconversion in dogs<br>
>>> vaccinated with FML vaccine (Leish-Immune) in <st1:country-region
w:st="on"><st1:place w:st="on">Brazil</st1:place></st1:country-region>.<br>
>>> Because we use released antigens in our kit,
any such<br>
>>> problems<br>
>>> will overcome if they use Canine Leish IgG CELISA (Manufacturer<br>
>>> Cellabs Pty Ltd Brookvale NSW Australia email<br>
>>> <mailto:<a href="mailto:sales@cellabs.com.au">sales@cellabs.com.au</a>>
<a href="mailto:sales@cellabs.com.au">sales@cellabs.com.au</a>).<br>
>>> If any one is interested to know more about
our antibody<br>
>>> detection ELISA based on exo-antigens please contact us.<br>
>>><br>
>>> This is for your kind information.<br>
>>><br>
>>> Dr GR Rajasekariah<br>
>>> <st1:City w:st="on"><st1:place w:st="on">Sydney</st1:place></st1:City><br>
>>> <st1:country-region w:st="on"><st1:place
w:st="on">Australia</st1:place></st1:country-region><br>
>>> <mailto:<a href="mailto:raj@cellabs.com.au">raj@cellabs.com.au</a>>
<a href="mailto:raj@cellabs.com.au">raj@cellabs.com.au</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> ----- Original Message ----- From: <<br>
>>> <mailto:<a href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</a>><br>
>>> To: < <mailto:<a
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> Sent: Wednesday, August 10, 2011 5:18 PM<br>
>>> Subject: Leish-l Digest, Vol 44, Issue 3<br>
>>><br>
>>> Send Leish-l mailing list submissions to<br>
>>><br>
>>> <mailto:<a
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a><br>
>>><br>
>>><br>
>>><br>
>>> To subscribe or
unsubscribe via the World Wide Web,<br>
>>> visit<br>
>>><br>
>>><br>
>>> <<a
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a>><br>
>>> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
>>><br>
>>> or, via email,
send a message with subject or body<br>
>>> 'help' to<br>
>>><br>
>>> <mailto:<a
href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</a><br>
>>><br>
>>><br>
>>><br>
>>> You can reach the
person managing the list at<br>
>>><br>
>>> <mailto:<a
href="mailto:leish-l-owner@lineu.icb.usp.br">leish-l-owner@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l-owner@lineu.icb.usp.br">leish-l-owner@lineu.icb.usp.br</a><br>
>>><br>
>>><br>
>>><br>
>>> When replying,
please edit your Subject line so it is<br>
>>> more specific<br>
>>><br>
>>> than "Re:
Contents of Leish-l digest..."<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> Today's Topics:<br>
>>><br>
>>><br>
>>><br>
>>> 1. European
VL Dog Vaccine - CaniLeish?: (jeffrey<br>
>>> shaw)<br>
>>><br>
>>> 2. Re: FW:
Leishmaniasis Pathology Network (Moazzem<br>
>>> Hossain)<br>
>>><br>
>>> 3. Re: FW:
Leishmaniasis Pathology Network (Moazzem<br>
>>> Hossain)<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
---------------------------------------------------------------------<br>
>>> -<br>
>>><br>
>>><br>
>>><br>
>>> Message: 1<br>
>>><br>
>>> Date: Tue, 9 Aug
2011 15:18:44 +0000<br>
>>><br>
>>> From: jeffrey
shaw < <mailto:<a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>><br>
>>> <a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>><br>
>>><br>
>>> Subject:
[Leish-l] European VL Dog Vaccine -<br>
>>> CaniLeish?:<br>
>>><br>
>>> To: Leish-L <
<mailto:<a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>><br>
>>> Message-ID: <<br>
>>> <mailto:<a
href="mailto:COL101-W1CDD4171D44B715B795E9CB200@phx.gbl">COL101-W1CDD4171D44B715B795E9CB200@phx.gbl</a>><br>
>>> COL101-W1CDD4171D44B715B795E9CB200@phx.gbl><br>
>>><br>
>>> Content-Type:
text/plain; charset="windows-1252"<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> CaniLeish?:<br>
>>><br>
>>> The
European Commission granted a marketing<br>
>>> authorisation valid throughout the European Union, for CaniLeish
to<br>
>>> Virbac S.A. on 14/03/2011.<br>
>>><br>
>>> This
vaccine, CaniLeish?, will initially be launched<br>
>>> in <st1:country-region w:st="on"><st1:place w:st="on">Portugal</st1:place></st1:country-region>
at the end of the first half of 2011. This will be<br>
>>> followed rapidly by launches in other countries in the endemic<br>
>>> area:<br>
>>> <st1:country-region w:st="on">Spain</st1:country-region>, <st1:country-region
w:st="on">France</st1:country-region>, <st1:country-region w:st="on">Greece</st1:country-region>
and <st1:country-region w:st="on"><st1:place w:st="on">Italy</st1:place></st1:country-region>
(not in chronological order). This<br>
>>> roll-out takes account of the geographical prevalence of the<br>
>>> disease<br>
>>> and the time required to build vaccine production up to full<br>
>>> capacity. The launch in Northern European countries from where<br>
>>> there<br>
>>> is a flow of summer visitors to the endemic area will be part of a<br>
>>> second phase.<br>
>>><br>
>>> The basis
of this vaccine are excreted proteins<br>
>>> plus<br>
>>> a saponin adjuvant purified from Quil-A. Its efficacy was<br>
>>> determined<br>
>>> in a<br>
>>> 2 year open field trial.<br>
>>><br>
>>> The
vaccine is given to dogs as three injections,<br>
>>> three weeks apart, under the skin. The first injection can be
given<br>
>>> from six months of age, the second injection is given three weeks<br>
>>> later and the third three weeks from the second one. Afterward a<br>
>>> single ?booster?<br>
>>> should be given every year to maintain protection.<br>
>>><br>
>>> --------------
next part --------------<br>
>>><br>
>>> An HTML
attachment was scrubbed...<br>
>>><br>
>>> URL: <<br>
>>><br>
>>> <<a
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404"
target="_blank">http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404</a><br>
>>> f5e<br>
>>> /attachment-0001.htm><br>
>>><br>
>>> <a
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f"
target="_blank">http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f</a><br>
>>> 5e/<br>
>>> attachment-0001.htm><br>
>>><br>
>>><br>
>>><br>
>>>
------------------------------<br>
>>><br>
>>><br>
>>><br>
>>> Message: 2<br>
>>><br>
>>> Date: Wed, 10 Aug
2011 13:07:17 +0600<br>
>>><br>
>>> From: Moazzem
Hossain <<br>
>>> <mailto:<a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a>><br>
>>> <a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a>><br>
>>><br>
>>> Subject: Re:
[Leish-l] FW: Leishmaniasis Pathology<br>
>>> Network<br>
>>><br>
>>> To: jeffrey shaw
< <mailto:<a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>><br>
>>> <a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>>,
"Prof. Paul Kaye"<br>
>>><br>
>>> < <mailto:<a
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>> <a
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>><br>
>>> Cc: "Prof.
Dr. Moazzem Hossain" <<br>
>>> <mailto:<a href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</a>><br>
>>> <a href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</a>>,<br>
>>><br>
>>> Leish-L <
<mailto:<a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>><br>
>>> Message-ID:<br>
>>><br>
>>> <<br>
>>><br>
>>> <mailto:<a href="mailto:CAE-TCmS">CAE-TCmS</a>=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmai<br>
>>> l.c<br>
>>> om><br>
>>> CAE-TCmS=i=WaT8cAeOXUJmot=<a
href="mailto:KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmail.co">KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmail.co</a><br>
>>> om> m><br>
>>><br>
>>> Content-Type:
text/plain; charset=windows-1252<br>
>>><br>
>>><br>
>>><br>
>>> 10 Aug 2011<br>
>>><br>
>>><br>
>>><br>
>>> Dear Professor
Paul Kaye,<br>
>>><br>
>>><br>
>>><br>
>>> Thank you for
your email. Please find attached our<br>
>>> supportive letter<br>
>>><br>
>>> of interest for
Leishmaniasis Pathology Network.<br>
>>><br>
>>> Looking forward
for your kind response.<br>
>>><br>
>>><br>
>>><br>
>>> Best regards.<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> --<br>
>>><br>
>>> *Prof. Dr.
Moazzem Hossain *<br>
>>><br>
>>> Ex - Director
Disease Control<br>
>>><br>
>>> Ministry of
Health & Family Welfare<br>
>>><br>
>>> Government of
<st1:country-region w:st="on"><st1:place w:st="on">Bangladesh</st1:place></st1:country-region><br>
>>><br>
>>> *Mailing
address*:<br>
>>><br>
>>> Founder Chairman
and Project Director<br>
>>><br>
>>> <st1:place w:st="on"><st1:PlaceType
w:st="on">Institute</st1:PlaceType> of <st1:PlaceName w:st="on">Allergy</st1:PlaceName></st1:place>
& Clinical Immunology of<br>
>>> <st1:country-region w:st="on"><st1:place w:st="on">Bangladesh</st1:place></st1:country-region><br>
>>> (IACIB)<br>
>>><br>
>>> Room 4 - 5 (2nd
Floor), Green Super Market, Green<br>
>>> Road<br>
>>><br>
>>> Dhaka -1205, <st1:country-region
w:st="on"><st1:place w:st="on">Bangladesh</st1:place></st1:country-region>.<br>
>>><br>
>>>
Phone:880-2-8115646 (O )<br>
>>><br>
>>>
880-1715038551(<st1:City w:st="on"><st1:place w:st="on">Mobile</st1:place></st1:City>)<br>
>>><br>
>>> Email:
<mailto:<a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a>><br>
>>> <a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> On 8/9/11,
jeffrey shaw < <mailto:<a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>><br>
>>> <a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>>
wrote:<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
Date: Tue, 9 Aug 2011 11:58:52 +0100<br>
>>><br>
>>>
From: <mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>> <a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a><br>
>>><br>
>>><br>
>>><br>
>>>
Subject: Leishmaniasis Pathology Network<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
Dear all,<br>
>>><br>
>>>
Invitation to participate in a global<br>
>>> pathology<br>
>>><br>
>>>
network for<br>
>>><br>
>>>
research and training in leishmaniasis<br>
>>> (LeishPathNet)<br>
>>><br>
>>>
You may recall the Dormy House meeting in<br>
>>> 2008<br>
>>><br>
>>>
and some of<br>
>>><br>
>>>
the plans we put forward? Over<br>
>>><br>
>>>
the past<br>
>>><br>
>>>
couple years, I have also spoken more to<br>
>>> a<br>
>>> few of you about one<br>
>>><br>
>>>
idea that was<br>
>>><br>
>>>
formulated at Dormy, namely of setting<br>
>>> up<br>
>>> a digital pathology<br>
>>><br>
>>>
network. I have<br>
>>><br>
>>>
also had numerous discussions with the<br>
>>> major equipment<br>
>>><br>
>>>
manufacturers to see if<br>
>>><br>
>>>
any of them would be supportive of<br>
>>> helping<br>
>>> us to develop such an<br>
>>><br>
>>>
initiative. There have<br>
>>><br>
>>>
been two major<br>
>>><br>
>>>
develoments recently. First,<br>
>>><br>
>>>
Carl Zeiss<br>
>>><br>
>>>
is willing to work with us to set up an<br>
>>> integrated global digital<br>
>>><br>
>>>
pathology<br>
>>><br>
>>>
network (providing a significant<br>
>>> financial<br>
>>> and technical<br>
>>><br>
>>>
contribution) and<br>
>>><br>
>>>
second, the Wellcome Trust is willing to<br>
>>> review a pre-proposal to<br>
>>><br>
>>>
fund the<br>
>>><br>
>>>
initiative through their new Biomedical<br>
>>> Resources Grant scheme<br>
>>><br>
>>>
(<br>
>>><br>
>>> <<a
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes"
target="_blank">http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes</a><br>
>>> /St rategic-awards-and-initiatives/wtdv031727.htm><br>
>>><br>
>>> <a
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/"
target="_blank">http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/</a><br>
>>> Str<br>
>>> ategic-awards-and-initiatives/wtdv031727.htm)<br>
>>><br>
>>>
.<br>
>>><br>
>>>
I have attached an outline of the project<br>
>>> that<br>
>>><br>
>>>
I had sent to<br>
>>><br>
>>>
the Trust for their initial views, which<br>
>>> I<br>
>>> think is reasonably<br>
>>><br>
>>>
self-explanatory.<br>
>>><br>
>>>
They appeared very<br>
>>><br>
>>>
enthusiastic! The main<br>
>>><br>
>>>
question now is whether enough of<br>
>>><br>
>>>
you are still supportive? [ I will also<br>
>>> be<br>
>>> sending this email to<br>
>>><br>
>>>
others, but please feel free to<br>
>>> circulate<br>
>>> ]<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
I think the<br>
>>><br>
>>>
project will be<br>
>>><br>
>>>
challenging, but success could have a<br>
>>> real impact on the way we<br>
>>><br>
>>>
conduct<br>
>>><br>
>>>
business. It should serve not
only as<br>
>>> a<br>
>>> vehicle to enhance<br>
>>><br>
>>>
research in<br>
>>><br>
>>>
leishmaniasis, but the model would be<br>
>>> equally applicable across<br>
>>><br>
>>>
a broad range<br>
>>><br>
>>>
of diseases and global challenges<br>
>>> (with<br>
>>> leishmaniasis setting<br>
>>><br>
>>>
the pace).<br>
>>><br>
>>>
If we wish to<br>
>>><br>
>>>
proceed, the requirements<br>
>>><br>
>>>
are that we submit a pre-proposal to<br>
>>> the<br>
>>> Trust by Oct 18th 2011.<br>
>>><br>
>>>
This pre-proposal is short (4 sections<br>
>>> of<br>
>>> 350 words) and<br>
>>><br>
>>>
requires<br>
>>><br>
>>>
letters of support from the community.<br>
>>><br>
>>>
If you are<br>
>>><br>
>>>
supportive of the idea that<br>
>>><br>
>>>
we try to take this forward (and there<br>
>>> is plenty of scope for<br>
>>><br>
>>>
later iteration<br>
>>><br>
>>>
of the detail), I would be grateful if<br>
>>> you could please provide<br>
>>><br>
>>>
me with a<br>
>>><br>
>>>
letter of support by September<br>
>>><br>
>>>
12th<br>
>>><br>
>>>
2011, indicating whether you
would<br>
>>> like to be a network<br>
>>><br>
>>>
partner if the bid<br>
>>><br>
>>>
is successful. You could<br>
>>><br>
>>>
also be<br>
>>><br>
>>>
supportive but not wish to become<br>
>>> directly involved at this<br>
>>><br>
>>>
stage, and such<br>
>>><br>
>>>
letters are equally valuable. Your<br>
>>> letter might also stress the<br>
>>><br>
>>>
added value<br>
>>><br>
>>>
that the network could provide, its<br>
>>> importance for research and<br>
>>><br>
>>>
training and/or<br>
>>><br>
>>>
for progressing the translational<br>
>>> agenda.<br>
>>><br>
>>>
It would also be an opportunity to<br>
>>> indicate whether your<br>
>>><br>
>>>
group (or<br>
>>><br>
>>>
institute, if multiple groups) would<br>
>>> be<br>
>>> interested in bidding to<br>
>>><br>
>>>
be one of the<br>
>>><br>
>>>
initial ?designated laboratories?.<br>
>>><br>
>>>
If there is<br>
>>><br>
>>>
sufficient support to<br>
>>><br>
>>>
proceed and if subsequently the<br>
>>> pre-proposal is successful (we<br>
>>><br>
>>>
will know on 22nd<br>
>>><br>
>>>
Nov), then I will need a few<br>
>>> volunteers<br>
>>> to help finalise the<br>
>>><br>
>>>
full proposal,<br>
>>><br>
>>>
which will be due on Jan 26th 2012.<br>
>>><br>
>>>
A funding decision will be made on May<br>
>>> 26th<br>
>>><br>
>>>
2012.<br>
>>><br>
>>>
Best wishes<br>
>>><br>
>>>
and of course I am happy to<br>
>>><br>
>>>
discuss any points further (though I<br>
>>> will be out of the <st1:country-region w:st="on"><st1:place w:st="on">UK</st1:place></st1:country-region>
from<br>
>>><br>
>>>
Aug 10 ?Sept<br>
>>><br>
>>>
12)<br>
>>><br>
>>>
Paul<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
--<br>
>>><br>
>>>
Professor Paul Kaye, Ph.D., FRCPath.<br>
>>><br>
>>>
Deputy Dean (Research), <st1:City w:st="on">Hull</st1:City> <st1:City
w:st="on"><st1:place w:st="on">York</st1:place></st1:City> Medical<br>
>>> School, and<br>
>>><br>
>>>
Director, Centre for Immunology and Infection<br>
>>><br>
>>>
Department of Biology and <st1:City w:st="on">Hull</st1:City> <st1:City
w:st="on"><st1:place w:st="on">York</st1:place></st1:City> Medical<br>
>>> School<br>
>>><br>
>>>
<st1:place w:st="on"><st1:PlaceType w:st="on">University</st1:PlaceType>
of <st1:PlaceName w:st="on">York</st1:PlaceName></st1:place><br>
>>><br>
>>>
Wentworth Way<br>
>>><br>
>>>
<st1:place w:st="on"><st1:City w:st="on">York</st1:City> <st1:PostalCode
w:st="on">YO10 5YW</st1:PostalCode></st1:place><br>
>>><br>
>>>
<st1:country-region w:st="on"><st1:place w:st="on">United Kingdom</st1:place></st1:country-region><br>
>>><br>
>>><br>
>>><br>
>>>
Tel: <a href="tel:%2B44%20%280%291904%20328840"
value="+441904328840">+44 (0)1904 328840</a><br>
>>><br>
>>>
Fax: <a href="tel:%2B44%20%280%291904%20328844"
value="+441904328844">+44 (0)1904 328844</a><br>
>>><br>
>>>
Email: <mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>> <a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>
< <mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>> mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>><br>
>>><br>
>>><br>
>>>
Centre Administrator and PA: Elizabeth<br>
>>> Greensted<br>
>>><br>
>>>
Tel: 01904 328845<br>
>>><br>
>>>
Email: <mailto:<a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>><br>
>>> <a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>
< <mailto:<a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>><br>
>>> mailto:<a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>><br>
>>><br>
>>><br>
>>><br>
>>>
Centre Email: <mailto:<a href="mailto:cii@york.ac.uk">cii@york.ac.uk</a>><br>
>>> <a href="mailto:cii@york.ac.uk">cii@york.ac.uk</a> <
<mailto:<a href="mailto:cii@york.ac.uk">cii@york.ac.uk</a>> mailto:<a
href="mailto:cii@york.ac.uk">cii@york.ac.uk</a>><br>
>>><br>
>>><br>
>>><br>
>>>
Centre website: <<a href="http://www.york.ac.uk/cii"
target="_blank">http://www.york.ac.uk/cii</a>><br>
>>> <a href="http://www.york.ac.uk/cii" target="_blank">http://www.york.ac.uk/cii</a><br>
>>><br>
>>><br>
>>><br>
>>>
Times Higher Education University of the Year<br>
>>> 2010<br>
>>><br>
>>><br>
>>><br>
>>>
Email disclaimer:<br>
>>> <<a href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target="_blank">http://www.york.ac.uk/docs/disclaimer/email.htm</a>><br>
>>> <a href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target="_blank">http://www.york.ac.uk/docs/disclaimer/email.htm</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
------------------------------<br>
>>><br>
>>><br>
>>><br>
>>> Message: 3<br>
>>><br>
>>> Date: Wed, 10 Aug
2011 13:06:47 +0600<br>
>>><br>
>>> From: Moazzem
Hossain <<br>
>>> <mailto:<a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a>><br>
>>> <a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a>><br>
>>><br>
>>> Subject: Re:
[Leish-l] FW: Leishmaniasis Pathology<br>
>>> Network<br>
>>><br>
>>> To: jeffrey shaw
< <mailto:<a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>><br>
>>> <a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>>,
"Prof. Paul Kaye"<br>
>>><br>
>>> < <mailto:<a
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>> <a
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>><br>
>>> Cc: "Prof.
Dr. Moazzem Hossain" <<br>
>>> <mailto:<a href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</a>><br>
>>> <a href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</a>>,<br>
>>><br>
>>> Leish-L <
<mailto:<a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><br>
>>><br>
>>> Message-ID:<br>
>>><br>
>>> <<br>
>>><br>
>>> <mailto:<a href="mailto:CAE-TCmQNUkZdNE5w%2BZ20bjLC-">CAE-TCmQNUkZdNE5w+Z20bjLC-</a>=vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmai<br>
>>> l.c<br>
>>> om><br>
>>> CAE-TCmQNUkZdNE5w+Z20bjLC-=<a
href="mailto:vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmail.co">vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmail.co</a><br>
>>> om> CAE-TCmQNUkZdNE5w+m><br>
>>><br>
>>> Content-Type:
text/plain; charset="windows-1252"<br>
>>><br>
>>><br>
>>><br>
>>> 10 Aug 2011<br>
>>><br>
>>><br>
>>><br>
>>> Dear Professor
Paul Kaye,<br>
>>><br>
>>><br>
>>><br>
>>> Thank you for
your email. Please find attached our<br>
>>> supportive letter<br>
>>><br>
>>> of interest for
Leishmaniasis Pathology Network.<br>
>>><br>
>>> Looking forward
for your kind response.<br>
>>><br>
>>><br>
>>><br>
>>> Best regards.<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> --<br>
>>><br>
>>> *Prof. Dr.
Moazzem Hossain *<br>
>>><br>
>>> Ex - Director
Disease Control<br>
>>><br>
>>> Ministry of
Health & Family Welfare<br>
>>><br>
>>> Government of
<st1:country-region w:st="on"><st1:place w:st="on">Bangladesh</st1:place></st1:country-region><br>
>>><br>
>>> *Mailing
address*:<br>
>>><br>
>>> Founder Chairman
and Project Director<br>
>>><br>
>>> <st1:place w:st="on"><st1:PlaceType
w:st="on">Institute</st1:PlaceType> of <st1:PlaceName w:st="on">Allergy</st1:PlaceName></st1:place>
& Clinical Immunology of<br>
>>> <st1:country-region w:st="on"><st1:place w:st="on">Bangladesh</st1:place></st1:country-region><br>
>>> (IACIB)<br>
>>><br>
>>> Room 4 - 5 (2nd
Floor), Green Super Market, Green<br>
>>> Road<br>
>>><br>
>>> Dhaka -1205, <st1:country-region
w:st="on"><st1:place w:st="on">Bangladesh</st1:place></st1:country-region>.<br>
>>><br>
>>>
Phone:880-2-8115646 (O )<br>
>>><br>
>>>
880-1715038551(<st1:City w:st="on"><st1:place w:st="on">Mobile</st1:place></st1:City>)<br>
>>><br>
>>> Email:
<mailto:<a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a>><br>
>>> <a href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> On 8/9/11,
jeffrey shaw < <mailto:<a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>><br>
>>> <a href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</a>>
wrote:<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
Date: Tue, 9 Aug 2011 11:58:52 +0100<br>
>>><br>
>>>
From: <mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>> <a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a><br>
>>><br>
>>><br>
>>><br>
>>>
Subject: Leishmaniasis Pathology Network<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
Dear all,<br>
>>><br>
>>>
Invitation to participate in a global<br>
>>> pathology<br>
>>><br>
>>>
network for<br>
>>><br>
>>>
research and training in leishmaniasis<br>
>>> (LeishPathNet)<br>
>>><br>
>>>
You may recall the Dormy House meeting in<br>
>>> 2008<br>
>>><br>
>>>
and some of<br>
>>><br>
>>>
the plans we put forward? Over<br>
>>><br>
>>>
the past<br>
>>><br>
>>>
couple years, I have also spoken more to<br>
>>> a<br>
>>> few of you about one<br>
>>><br>
>>>
idea that was<br>
>>><br>
>>>
formulated at Dormy, namely of setting<br>
>>> up<br>
>>> a digital pathology<br>
>>><br>
>>>
network. I have<br>
>>><br>
>>>
also had numerous discussions with the<br>
>>> major equipment<br>
>>><br>
>>>
manufacturers to see if<br>
>>><br>
>>>
any of them would be supportive of<br>
>>> helping<br>
>>> us to develop such an<br>
>>><br>
>>>
initiative. There have<br>
>>><br>
>>>
been two major<br>
>>><br>
>>>
develoments recently. First,<br>
>>><br>
>>>
Carl Zeiss<br>
>>><br>
>>>
is willing to work with us to set up an<br>
>>> integrated global digital<br>
>>><br>
>>>
pathology<br>
>>><br>
>>>
network (providing a significant<br>
>>> financial<br>
>>> and technical<br>
>>><br>
>>>
contribution) and<br>
>>><br>
>>>
second, the Wellcome Trust is willing to<br>
>>> review a pre-proposal to<br>
>>><br>
>>>
fund the<br>
>>><br>
>>>
initiative through their new Biomedical<br>
>>> Resources Grant scheme<br>
>>><br>
>>>
(<br>
>>><br>
>>> <<a
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes"
target="_blank">http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes</a><br>
>>> /St rategic-awards-and-initiatives/wtdv031727.htm><br>
>>><br>
>>> <a
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/"
target="_blank">http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/</a><br>
>>> Str<br>
>>> ategic-awards-and-initiatives/wtdv031727.htm)<br>
>>><br>
>>>
.<br>
>>><br>
>>>
I have attached an outline of the project<br>
>>> that<br>
>>><br>
>>>
I had sent to<br>
>>><br>
>>>
the Trust for their initial views, which<br>
>>> I<br>
>>> think is reasonably<br>
>>><br>
>>>
self-explanatory.<br>
>>><br>
>>>
They appeared very<br>
>>><br>
>>>
enthusiastic! The main<br>
>>><br>
>>>
question now is whether enough of<br>
>>><br>
>>>
you are still supportive? [ I will also<br>
>>> be<br>
>>> sending this email to<br>
>>><br>
>>>
others, but please feel free to<br>
>>> circulate<br>
>>> ]<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
I think the<br>
>>><br>
>>>
project will be<br>
>>><br>
>>>
challenging, but success could have a<br>
>>> real impact on the way we<br>
>>><br>
>>>
conduct<br>
>>><br>
>>>
business. It should serve not
only as<br>
>>> a<br>
>>> vehicle to enhance<br>
>>><br>
>>>
research in<br>
>>><br>
>>>
leishmaniasis, but the model would be<br>
>>> equally applicable across<br>
>>><br>
>>>
a broad range<br>
>>><br>
>>>
of diseases and global challenges<br>
>>> (with<br>
>>> leishmaniasis setting<br>
>>><br>
>>>
the pace).<br>
>>><br>
>>>
If we wish to<br>
>>><br>
>>>
proceed, the requirements<br>
>>><br>
>>>
are that we submit a pre-proposal to<br>
>>> the<br>
>>> Trust by Oct 18th 2011.<br>
>>><br>
>>>
This pre-proposal is short (4 sections<br>
>>> of<br>
>>> 350 words) and<br>
>>><br>
>>>
requires<br>
>>><br>
>>>
letters of support from the community.<br>
>>><br>
>>>
If you are<br>
>>><br>
>>>
supportive of the idea that<br>
>>><br>
>>>
we try to take this forward (and there<br>
>>> is plenty of scope for<br>
>>><br>
>>>
later iteration<br>
>>><br>
>>>
of the detail), I would be grateful if<br>
>>> you could please provide<br>
>>><br>
>>>
me with a<br>
>>><br>
>>>
letter of support by September<br>
>>><br>
>>>
12th<br>
>>><br>
>>>
2011, indicating whether you
would<br>
>>> like to be a network<br>
>>><br>
>>>
partner if the bid<br>
>>><br>
>>>
is successful. You could<br>
>>><br>
>>>
also be<br>
>>><br>
>>>
supportive but not wish to become<br>
>>> directly involved at this<br>
>>><br>
>>>
stage, and such<br>
>>><br>
>>>
letters are equally valuable. Your<br>
>>> letter might also stress the<br>
>>><br>
>>>
added value<br>
>>><br>
>>>
that the network could provide, its<br>
>>> importance for research and<br>
>>><br>
>>>
training and/or<br>
>>><br>
>>>
for progressing the translational<br>
>>> agenda.<br>
>>><br>
>>>
It would also be an opportunity to<br>
>>> indicate whether your<br>
>>><br>
>>>
group (or<br>
>>><br>
>>>
institute, if multiple groups) would<br>
>>> be<br>
>>> interested in bidding to<br>
>>><br>
>>>
be one of the<br>
>>><br>
>>>
initial ?designated laboratories?.<br>
>>><br>
>>>
If there is<br>
>>><br>
>>>
sufficient support to<br>
>>><br>
>>>
proceed and if subsequently the<br>
>>> pre-proposal is successful (we<br>
>>><br>
>>>
will know on 22nd<br>
>>><br>
>>>
Nov), then I will need a few<br>
>>> volunteers<br>
>>> to help finalise the<br>
>>><br>
>>>
full proposal,<br>
>>><br>
>>>
which will be due on Jan 26th 2012.<br>
>>><br>
>>>
A funding decision will be made on May<br>
>>> 26th<br>
>>><br>
>>>
2012.<br>
>>><br>
>>>
Best wishes<br>
>>><br>
>>>
and of course I am happy to<br>
>>><br>
>>>
discuss any points further (though I<br>
>>> will be out of the <st1:country-region w:st="on"><st1:place w:st="on">UK</st1:place></st1:country-region>
from<br>
>>><br>
>>>
Aug 10 ?Sept<br>
>>><br>
>>>
12)<br>
>>><br>
>>>
Paul<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
--<br>
>>><br>
>>>
Professor Paul Kaye, Ph.D., FRCPath.<br>
>>><br>
>>>
Deputy Dean (Research), <st1:City w:st="on">Hull</st1:City> <st1:City
w:st="on"><st1:place w:st="on">York</st1:place></st1:City> Medical<br>
>>> School, and<br>
>>><br>
>>>
Director, Centre for Immunology and Infection<br>
>>><br>
>>>
Department of Biology and <st1:City w:st="on">Hull</st1:City> <st1:City
w:st="on"><st1:place w:st="on">York</st1:place></st1:City> Medical<br>
>>> School<br>
>>><br>
>>>
<st1:place w:st="on"><st1:PlaceType w:st="on">University</st1:PlaceType>
of <st1:PlaceName w:st="on">York</st1:PlaceName></st1:place><br>
>>><br>
>>>
Wentworth Way<br>
>>><br>
>>>
<st1:place w:st="on"><st1:City w:st="on">York</st1:City> <st1:PostalCode
w:st="on">YO10 5YW</st1:PostalCode></st1:place><br>
>>><br>
>>>
<st1:country-region w:st="on"><st1:place w:st="on">United Kingdom</st1:place></st1:country-region><br>
>>><br>
>>><br>
>>><br>
>>>
Tel: <a href="tel:%2B44%20%280%291904%20328840"
value="+441904328840">+44 (0)1904 328840</a><br>
>>><br>
>>>
Fax: <a href="tel:%2B44%20%280%291904%20328844"
value="+441904328844">+44 (0)1904 328844</a><br>
>>><br>
>>>
Email: <mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>> <a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>
< <mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>> mailto:<a href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</a>><br>
>>><br>
>>><br>
>>><br>
>>>
Centre Administrator and PA: Elizabeth<br>
>>> Greensted<br>
>>><br>
>>>
Tel: 01904 328845<br>
>>><br>
>>>
Email: <mailto:<a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>><br>
>>> <a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>
< <mailto:<a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>><br>
>>> mailto:<a href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</a>><br>
>>><br>
>>><br>
>>><br>
>>>
Centre Email: <mailto:<a href="mailto:cii@york.ac.uk">cii@york.ac.uk</a>><br>
>>> <a href="mailto:cii@york.ac.uk">cii@york.ac.uk</a> <
<mailto:<a href="mailto:cii@york.ac.uk">cii@york.ac.uk</a>> mailto:<a
href="mailto:cii@york.ac.uk">cii@york.ac.uk</a>><br>
>>><br>
>>><br>
>>><br>
>>>
Centre website: <<a href="http://www.york.ac.uk/cii"
target="_blank">http://www.york.ac.uk/cii</a>><br>
>>> <a href="http://www.york.ac.uk/cii" target="_blank">http://www.york.ac.uk/cii</a><br>
>>><br>
>>><br>
>>><br>
>>>
Times Higher Education University of the Year<br>
>>> 2010<br>
>>><br>
>>><br>
>>><br>
>>>
Email disclaimer:<br>
>>> <<a href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target="_blank">http://www.york.ac.uk/docs/disclaimer/email.htm</a>><br>
>>> <a href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target="_blank">http://www.york.ac.uk/docs/disclaimer/email.htm</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> --------------
next part --------------<br>
>>><br>
>>> A non-text
attachment was scrubbed...<br>
>>><br>
>>> Name: Letter
Leish UK.doc<br>
>>><br>
>>> Type: application/msword<br>
>>><br>
>>> Size: 46080 bytes<br>
>>><br>
>>> Desc: not
available<br>
>>><br>
>>> URL: <<br>
>>><br>
>>> <<a
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2a"
target="_blank">http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2a</a><br>
>>> e6a<br>
>>> /attachment.doc><br>
>>><br>
>>> <a
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae"
target="_blank">http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae</a><br>
>>> 6a/<br>
>>> attachment.doc><br>
>>><br>
>>><br>
>>><br>
>>>
------------------------------<br>
>>><br>
>>><br>
>>><br>
>>>
_______________________________________________<br>
>>><br>
>>> Leish-l mailing
list<br>
>>><br>
>>> <mailto:<a
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a>><br>
>>> <a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
>>><br>
>>><br>
>>> <<a
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a>><br>
>>> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> End of Leish-l
Digest, Vol 44, Issue 3<br>
>>><br>
>>>
**************************************<br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>> =======<br>
>>> Email scanned by PC Tools - No viruses or
spyware found.<br>
>>> (Email Guard: 7.0.0.26, Virus/Spyware
Database: 6.18330)<br>
>>> <<a href="http://www.pctools.com/"
target="_blank">http://www.pctools.com/</a>> <a
href="http://www.pctools.com/" target="_blank">http://www.pctools.com/</a><br>
>>> =======<br>
>>>
_______________________________________________<br>
>>> Leish-l mailing list<br>
>>> <mailto:<a
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a>> <a
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
>>> <<a
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a>><br>
>>> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>><br>
>>>
_______________________________________________<br>
>>> Leish-l mailing list<br>
>>> <a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
>>> <a
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
>>><br>
>>><br>
>><br>
>><br>
>><br>
>><br>
>> _______________________________________________<br>
>> Leish-l mailing list<br>
>> <a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
>> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
>><br>
>> --<br>
>> This message has been scanned for viruses and dangerous content by<br>
>> MailScanner, and is believed to be clean.<br>
>><br>
>><br>
>> ######################################################################<br>
>> ############### This e-mail message has been scanned for Viruses and<br>
>> Content and cleared by MailMarshal<br>
>><br>
>> ######################################################################<br>
>> ############### _______________________________________________<br>
>> Leish-l mailing list<br>
>> <a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
>> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
>><br>
>><br>
>> _______________________________________________<br>
>> Leish-l mailing list<br>
>> <a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
>> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
>><br>
><br>
><br>
><br>
> _______________________________________________<br>
> Leish-l mailing list<br>
> <a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
> _______________________________________________<br>
> Leish-l mailing list<br>
> <a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
> <a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br>
_______________________________________________<br>
Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br>
_______________________________________________<br>
Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><o:p></o:p></span></font></p>
</div>
</div>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><br>
<br clear=all>
<o:p></o:p></span></font></p>
<div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'>-- <o:p></o:p></span></font></p>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>Carlos H. N. Costa, MD, DSc.</span></font></b><o:p></o:p></p>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>Sociedade Brasileira de Medicina Tropical </span></font></b><o:p></o:p></p>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>(Brazilian Society of Tropical Medicine)</span></font></b><o:p></o:p></p>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>President</span></font></b><o:p></o:p></p>
<p class=MsoNormal align=center style='text-align:center'><font size=3
face="Times New Roman"><span style='font-size:12.0pt'><o:p> </o:p></span></font></p>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>Universidade Federal do Piauí</span></font></b><o:p></o:p></p>
<div>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>Instituto de Doenças Tropicais Natan Portella</span></font></b><o:p></o:p></p>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>Rua Artur de Vasconcelos 151-Sul</span></font></b><o:p></o:p></p>
<div>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>64001-450 Teresina-PI</span></font></b><o:p></o:p></p>
<p class=MsoNormal align=center style='text-align:center'><st1:country-region
w:st="on"><st1:place w:st="on"><b><font size=3 face=Verdana><span
style='font-size:12.0pt;font-family:Verdana;font-weight:bold'>Brazil</span></font></b></st1:place></st1:country-region><font
face=Verdana><span style='font-family:Verdana'><o:p></o:p></span></font></p>
<p class=MsoNormal align=center style='text-align:center'><b><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana;font-weight:
bold'>Telephones: +55 86 3221-3413 (work); +55 86 8838-3303 (mobile).<o:p></o:p></span></font></b></p>
<p class=MsoNormal align=center style='text-align:center'><font size=3
face=Verdana><span style='font-size:12.0pt;font-family:Verdana'><o:p> </o:p></span></font></p>
<p class=MsoNormal align=center style='text-align:center'><font size=2
face=Verdana><span style='font-size:10.0pt;font-family:Verdana'>Aviso: As
informações contidas nesta mensagem são CONFIDENCIAIS, protegidas pelo sigilo
legal, por direitos autorais e destinadas exclusivamente à pessoa ou
organização para a qual a mensagem foi destinada.<o:p></o:p></span></font></p>
<p class=MsoNormal align=center style='text-align:center'><font size=2
face=Verdana><span style='font-size:10.0pt;font-family:Verdana'>Warning: This
message is meant only for the intended recipient of the transmission. It
is forbidden any unauthorized use, alteration, reproduction and distribution.
If you are not the correct recipient, please notify us immediately by return
e-mail and delete this message from your system.<o:p></o:p></span></font></p>
</div>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
</div>
</div>
</body>
</html>